Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Leukemia, Biphenotypic, Acute 1

Interventions

Dexamethasone 10Cyclophosphamide 9Cytarabine 7venetoclax 6Vincristine 6Methotrexate 5blinatumomab 4Prednisone 4Inotuzumab Ozogamicin 4Doxorubicin 4Rituximab 3prednylidene 2pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2deltacortene 2Mercaptopurine 2Etoposide 2Decitabine 2Calcium Dobesilate 2trametinib 1ruxolitinib 1olverembatinib 1ofatumumab 1nilotinib 1navitoclax 1fludarabine 1capivasertib 1azathiopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡